Introduction
The global antidepressant market has seen extraordinary growth over the last
decade. However, with few entrants and a flood of patent expiries by 2009, the
dynamics of this $16.9 billion market are set to undergo a major change. As
generic competition intensifies, companies need to carefully re-examine their
strategies if they wish to protect their market share.
Key findings and highlights
- Antidepressant sales are expected to decrease by -21.5% to $13.5 billion
by 2011. During the forecast period 2003-11, the market will experience a
period of high volatility as revenues are impacted by consecutive patent
expiries and limited product launches.
- The serotonergic class dominates the market, accounting for 57.6% of
market share in 2002. However, all of the leading brands will suffer patent
expiries by 2009. As physicians are encouraged to utilize cheaper generics,
brand players must look towards maximizing revenues through product
differentiation and innovative lifecycle strategies.
- Wyeth' s noradrenergic, Effexor has positioned itself as a relatively
unique product in the antidepressant market. However, with Lilly' s Cymbalta
demonstrating a similar mode of action and anticipated to launch in mid
2004, Effexor is expected to undergo its first major challenge to its market
position.
Reasons to buy
- Assess leading antidepressants and identify key success factors within
this sector
- Understand key market drivers and predict the future performance of key
compounds
- Benchmark pipeline antidepressants against currently marketed products
and assess their future market potential
View Cart
